Generic Prostate Cancer Drugs Undergoing FDA Safety Review

The FDA is conducting a safety review of a class of commonly used prostate cancer drugs, including generics, in light of a safety signal showing they may pose a small increased risk for diabetes and cardiovascular disease in men. Preliminary and ongoing studies of the gonadotropin-releasing hormone agonists, which reduce the production of testosterone for androgen deprivation therapy, show the drugs have been associated with diabetes as well as heart attack, stroke and sudden death in men. However, the FDA said it has not made any conclusions about whether the drugs actually increase those risks.
Generic Line